merck - Search News

Merck KGaA Forecasts Earnings, Sales Growth

Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production.

The Wall Street Journal on MSN · 12h

Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced research and development expenses in its healthcare segment and strict cost discipline.

Seeking Alpha · 2h

Merck KGaA (MKGAF) Q4 2024 Earnings Call Transcript

Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor

Bloomberg L.P. · 12h

Merck KGaA Sees Slow Profit Growth This Year Amid Recovery

Merck KGaA forecast slow profit growth for this year as its life science business continues to recover and the boom in AI lifts demand at its semiconductor division.

Merck, Keytruda and patent

The Wall Street Journal on MSN · 23h

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Markets Insider · 1d

Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a new version of

Reuters on MSN · 1d

New version of Merck's Keytruda faces possible patent battle, WSJ reports

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

The Reporter29m

Merck seeks to trade wetlands for potential to add parking or building

What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...

Fierce Biotech7h

Merck KGaA fails midphase lupus trial, says totality of data support further development

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

Delaware approves $30.2 million taxpayer-funded grant for Merck to build in state

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

12d

Is Merck Stock a Buy?

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck expects cancer therapy Keytruda to be part of government price setting in 2026

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Merck's Oncology Strength: Beating Wall Street Again

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Fierce Pharma3h

In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck Manuals: What Patients Need to Know About Sinusitis and Sinus Infections

A sinus infection, known as sinusitis, is one of the most common medical conditions. But in some cases, it can come with dangerous complications.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Merck KGaA Forecasts Earnings, Sales Growth

Merck, Keytruda and patent

Related topics